Is Lisata Therapeutics Stock a Good Investment?
Lisata Therapeutics Investment Advice | LSTA |
- Examine Lisata Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Lisata Therapeutics' leadership team and their track record. Good management can help Lisata Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Lisata Therapeutics' business and its evolving consumer preferences.
- Compare Lisata Therapeutics' performance and market position to its competitors. Analyze how Lisata Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Lisata Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Lisata Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Lisata Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Lisata Therapeutics is a good investment.
Sell | Buy |
Sell
Market Performance | Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Lisata Therapeutics Stock
Researching Lisata Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 19.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.72. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Lisata Therapeutics recorded a loss per share of 2.51. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 15th of September 2022.
To determine if Lisata Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Lisata Therapeutics' research are outlined below:
| Lisata Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (20.84 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Lisata Therapeutics currently holds about 72.99 M in cash with (20.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 19.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: The Dr. James Morales Grant for Medicine and Biosciences Invites Undergraduate Scholars to Apply |
Lisata Therapeutics Quarterly Good Will |
|
Lisata Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Lisata Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Lisata Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Lisata Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Lisata Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-12 | 2024-06-30 | -0.76 | -0.61 | 0.15 | 19 | ||
2024-11-01 | 2024-09-30 | -0.77 | -0.59 | 0.18 | 23 | ||
2023-08-14 | 2023-06-30 | -0.7 | -0.5 | 0.2 | 28 | ||
2022-08-04 | 2022-06-30 | -1.45 | -1.65 | -0.2 | 13 | ||
2024-02-29 | 2023-12-31 | -0.89 | -0.66 | 0.23 | 25 | ||
2023-03-30 | 2022-12-31 | -1.01 | -0.76 | 0.25 | 24 | ||
2023-11-02 | 2023-09-30 | -0.93 | -0.65 | 0.28 | 30 | ||
2022-05-05 | 2022-03-31 | -1.45 | -1.05 | 0.4 | 27 |
Know Lisata Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lisata Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lisata Therapeutics backward and forwards among themselves. Lisata Therapeutics' institutional investor refers to the entity that pools money to purchase Lisata Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Founders Capital Management Inc | 2024-06-30 | 2 K | Citigroup Inc | 2024-06-30 | 1.4 K | Tower Research Capital Llc | 2024-06-30 | 440 | Royal Bank Of Canada | 2024-06-30 | 52.0 | Jpmorgan Chase & Co | 2024-06-30 | 16.0 | Steward Partners Investment Advisory, Llc | 2024-06-30 | 6.0 | Barclays Plc | 2024-06-30 | 4.0 | Wells Fargo & Co | 2024-06-30 | 1.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 1.0 | Bml Capital Management Llc | 2024-09-30 | 284.7 K | Vanguard Group Inc | 2024-09-30 | 186.4 K |
Lisata Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 24.18 M.Market Cap |
|
Lisata Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.53) | (0.56) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | (0.43) | (0.45) |
Determining Lisata Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Lisata Therapeutics is a good buy. For example, gross profit margin measures Lisata Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Lisata Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Lisata Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lisata Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Lisata Therapeutics' management manipulating its earnings.
Evaluate Lisata Therapeutics' management efficiency
Lisata Therapeutics has return on total asset (ROA) of (0.2872) % which means that it has lost $0.2872 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4403) %, meaning that it created substantial loss on money invested by shareholders. Lisata Therapeutics' management efficiency ratios could be used to measure how well Lisata Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 24, 2024, Return On Tangible Assets is expected to decline to -0.4. In addition to that, Return On Capital Employed is expected to decline to -0.56. At present, Lisata Therapeutics' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 1.5 M, whereas Total Assets are forecasted to decline to about 43.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.93 | 6.23 | |
| Tangible Book Value Per Share | 5.90 | 6.20 | |
| Enterprise Value Over EBITDA | 0.01 | 0.01 | |
| Price Book Value Ratio | 0.46 | 0.48 | |
| Enterprise Value Multiple | 0.01 | 0.01 | |
| Price Fair Value | 0.46 | 0.48 | |
| Enterprise Value | 25.9 M | 36.1 M |
Understanding the operational decisions made by Lisata Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 1.224 |
Basic technical analysis of Lisata Stock
As of the 24th of November, Lisata Therapeutics secures the Mean Deviation of 2.67, downside deviation of 3.43, and Risk Adjusted Performance of 0.0273. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lisata Therapeutics, as well as the relationship between them.Lisata Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lisata Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lisata Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lisata Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
James Nisco over six months ago Disposition of 4000 shares by James Nisco of Lisata Therapeutics at 3.08 subject to Rule 16b-3 | ||
James Nisco over six months ago Disposition of 3000 shares by James Nisco of Lisata Therapeutics at 3.0 subject to Rule 16b-3 | ||
James Nisco over six months ago Disposition of 4000 shares by James Nisco of Lisata Therapeutics at 3.08 subject to Rule 16b-3 | ||
Buck Kristen K over six months ago Disposition of 50103 shares by Buck Kristen K of Lisata Therapeutics at 1.28 subject to Rule 16b-3 | ||
Wei Eric 1 over a year ago Lisata Therapeutics exotic insider transaction detected |
Understand Lisata Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Lisata Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0273 | |||
| Market Risk Adjusted Performance | 0.1217 | |||
| Mean Deviation | 2.67 | |||
| Semi Deviation | 3.07 | |||
| Downside Deviation | 3.43 | |||
| Coefficient Of Variation | 3961.79 | |||
| Standard Deviation | 3.75 | |||
| Variance | 14.09 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.51) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.1117 | |||
| Maximum Drawdown | 19.57 | |||
| Value At Risk | (5.33) | |||
| Potential Upside | 7.53 | |||
| Downside Variance | 11.75 | |||
| Semi Variance | 9.43 | |||
| Expected Short fall | (3.24) | |||
| Skewness | 0.7558 | |||
| Kurtosis | 1.13 |
| Risk Adjusted Performance | 0.0273 | |||
| Market Risk Adjusted Performance | 0.1217 | |||
| Mean Deviation | 2.67 | |||
| Semi Deviation | 3.07 | |||
| Downside Deviation | 3.43 | |||
| Coefficient Of Variation | 3961.79 | |||
| Standard Deviation | 3.75 | |||
| Variance | 14.09 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.51) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.1117 | |||
| Maximum Drawdown | 19.57 | |||
| Value At Risk | (5.33) | |||
| Potential Upside | 7.53 | |||
| Downside Variance | 11.75 | |||
| Semi Variance | 9.43 | |||
| Expected Short fall | (3.24) | |||
| Skewness | 0.7558 | |||
| Kurtosis | 1.13 |
Consider Lisata Therapeutics' intraday indicators
Lisata Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Lisata Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Lisata Therapeutics Corporate Filings
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 2nd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 21st of August 2024 Other Reports | ViewVerify | |
| 15th of July 2024 Other Reports | ViewVerify |
Lisata Stock media impact
Far too much social signal, news, headlines, and media speculation about Lisata Therapeutics that are available to investors today. That information is available publicly through Lisata media outlets and privately through word of mouth or via Lisata internal channels. However, regardless of the origin, that massive amount of Lisata data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lisata Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lisata Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lisata Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lisata Therapeutics alpha.
Lisata Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Lisata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Lisata Therapeutics Corporate Management
| Kristen MD | Executive Officer | Profile | |
| Gail Holler | Vice Resources | Profile | |
| James Nisco | Treasurer, Finance | Profile | |
| Tariq Imam | Vice Counsel | Profile | |
| Ian MBA | Inc NeoStem | Profile | |
| Gregory Berkin | Chief Officer | Profile | |
| John Menditto | Vice Communications | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lisata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lisata Therapeutics. If investors know Lisata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lisata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.51) | Return On Assets (0.29) | Return On Equity (0.44) |
The market value of Lisata Therapeutics is measured differently than its book value, which is the value of Lisata that is recorded on the company's balance sheet. Investors also form their own opinion of Lisata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lisata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lisata Therapeutics' market value can be influenced by many factors that don't directly affect Lisata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Lisata Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Lisata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lisata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.